GlobeNewswire
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities
📈
AI Sentiment
Highly Positive
8/10
Biofrontera Inc. News
Latest updates and market news for BFRI
2 news
Dec 2 - Dec 8, 2025
Page 1
GlobeNewswire
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
📈
AI Sentiment
Highly Positive
8/10
Share this news page